The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical.
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 2 MS Study
USA - English
News provided by
Share this article
Share this article
NEW YORK, Dec. 18, 2020 /PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing has been completed in the ongoing Phase 2 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for progressive MS. The Phase 2 open-label clinical trial of repeat-dosing CSF-delivered autologous MSC-NTF cells (NurOwnâ) is being conducted at five clinical trial sites in the United States. Completed dosing of the Phase 2 progressive MS clinical trial is a major milestone for BrainStorm as we advance our goal to develop the NurOwn platform technology in neurodegenerative diseases, said Chaim Lebovits BrainStorm CEO. We are very thankful for the dedicated efforts of the investigators and their teams and to the patients who participa